Meet Our Editorial Board Member

Gary received his Ph.D. in physical/organic chemistry from Indiana University in 1982 under the direction of Dr. John E. Bartmess using Ion Cyclotron Resonance Spectrometry to study gas-phase ion chemistry. Following his Ph.D., he performed postdoctoral research with Dr. Paul Kebarle at the University of Alberta in Canada using High-Pressure Mass Spectrometry to study gas-phase ion chemistry. Gary joined Janssen Pharmaceutical Research and Development a subsidiary of Johnson & Johnson in 1985. During his 32-year career with Janssen Pharmaceutical R & D, Gary has managed a variety of functions within the drug discovery units. These functions include the NMR, GC/MS & LC/MS/MS spectroscopy group, the medicinal chemistry intermediates group, the large-scale separation group, the drug discovery in-vivo/in-vitro PK/ADME groups and the compound management group. His research interests primarily involve the use of advanced spectrometric and chromatographic techniques to chemically and biologically characterize new drug targets and drug entities. Presently, he is working on establishing targeted and untargeted metabolomic methods to understand “on” and “off” target effects to improve drug efficacy and reduce drug toxicity. He is the author of over 150 publications, two patents, over 50 poster presentations, and has given over 40 invited talks at universities, companies, and conferences. He is the co-editor of Frontier in Drug Design & Discovery (volumes 1-4), editor of Optimization in Drug Discovery: In-Vitro Methods (volumes 1-2).